Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04586062
Expanded Access Status : Available
First Posted : October 14, 2020
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
Kedrion S.p.A.

Brief Summary:
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.

Condition or disease Intervention/treatment
Ligneous Conjunctivitis Drug: Plasminogen

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
Official Title: Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population



Intervention Details:
  • Drug: Plasminogen
    Human Plasminogen

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Subjects diagnosed with LC associated with Type I plasminogen deficiency, confirmed by laboratory documentation at screening visit, with or without ocular pseudomembranes. The presence of membranes in different areas is not an exclusion criterion.
  • Subjects and their legally authorized representative, in the case of subjects <18 years of age, should be informed of the nature of the treatment, agree to its provision, sign and date the informed and data handling consent forms approved by the IRB.
  • Subjects must be available for the duration of the treatment and agree to be compliant with the protocol visit and follow-up schedule.
  • Subjects agree to keep the treating physician or specialist in charge informed about any occurrence related to the treatment.

Exclusion Criteria:

  • Subjects with any condition which, in the opinion of the treating physician or specialist in charge might interfere with the treatment.
  • Females of childbearing potential who are either pregnant or not using an adequate method of birth control (adequate is defined as hormonal contraceptive or partner vasectomy for at least 3 months, condoms, intrauterine device [IUD], abstinence or other prescribed birth control). Enrolled males must agree to utilize appropriate contraceptive methods to prevent pregnancy in partners.
  • Females who are breastfeeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04586062


Contacts
Layout table for location contacts
Contact: Anna Lotti Suffredini 00390583767324 a.lotti@kedrion.com
Contact: Laura Pino 00390583767310 l.pino@kedrion.com

Sponsors and Collaborators
Kedrion S.p.A.
Layout table for additonal information
Responsible Party: Kedrion S.p.A.
ClinicalTrials.gov Identifier: NCT04586062    
Other Study ID Numbers: SIEA-PLG
First Posted: October 14, 2020    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctivitis
Conjunctival Diseases
Eye Diseases
Plasminogen
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action